This is the only fully funded Specialized Research Center of the National Institute of Neurological Disease and Stroke on primary and metastatic brain tumors of adults and children. It is presently in its 10th year of funding and this application represents its third submission for competitive review and renewal. As detailed in the body of this application, both primary and metastatic tumors to the CNS remain as significant health problems and are actually increasing in magnitude. Despite intensive research efforts by many investigators there has been little progress made in uncovering etiology, or improving treatment of primary or metastatic brain tumors during the last 30 years. This Specialized Research Center on Primary and Malignant Tumors of the CNS will continue intensification of the brain tumor research efforts of an outstanding group of internationally recognized investigators with a long history of effective collaboration. They will approach primary and metastatic brain tumors in adults and children in areas of etiology, mechanisms of transformation and altered growth control, improved diagnosis, preclinical and clinical therapy. Projects range from basic mechanistic studies on etiology such as tumor suppressor genes in human medulloblastoma, discovery of new drugs and mechanisms of drug resistance, to selection of molecular targets against adult and childhood brain tumors for targeted therapy and growth inhibition. Specific development of targeted therapy with radiolabeled and toxin-conjugated; preclinical and clinical trials of regional or compartmental therapy with radiolabeled MAbs, toxin-conjugated MAbs, and new drugs will ultimately be combined in years 3-5 with Phase 2 and 3 studies of systemic therapy with regional and compartmental therapy to reach tumor cells in the entire neuraxis. We believe that during this five year grant period better control of local and distant recurrence of primary and metastatic brain tumors can be achieved, improvement can be made in therapy of neoplastic meningitis, and quality and quantity of survival of both groups of patients will be improved. Moreover, our basic studies should define new molecular targets for future approach in 5-10 years with additional targeted therapy such as gene therapy replacement of putative suppressor genes and gene therapy of other molecular targets involved in transformation and altered growth control.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS020023-19
Application #
6499332
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Finkelstein, Robert
Project Start
1984-04-01
Project End
2004-01-31
Budget Start
2002-02-01
Budget End
2003-01-31
Support Year
19
Fiscal Year
2002
Total Cost
$1,091,364
Indirect Cost
Name
Duke University
Department
Pathology
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Slastnikova, Tatiana A; Rosenkranz, Andrey A; Zalutsky, Michael R et al. (2015) Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des 21:1227-38
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9
Choi, Bryan D; Suryadevara, Carter M; Gedeon, Patrick C et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21:189-90
Brown, Michael C; Dobrikova, Elena Y; Dobrikov, Mikhail I et al. (2014) Oncolytic polio virotherapy of cancer. Cancer 120:3277-86
Miao, Hongsheng; Choi, Bryan D; Suryadevara, Carter M et al. (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9:e94281
Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25
Lathia, Justin D; Li, Meizhang; Sinyuk, Maksim et al. (2014) High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 6:117-29

Showing the most recent 10 out of 146 publications